Appropriateness of Sildenafil Prescribing in Pulmonary Hypertension with Valvular Heart Disease: A Single Centre Study [PDF]
Trends in Pharmaceutical Sciences, 2022 Oral sildenafil has proven efficacy in pulmonary hypertension in current clinical practice. However, there is a research gap in sildenafil prescribing among patients with valvular heart disease (VHD) and pulmonary hypertension (PH) in Malaysia.
Tze Hoon Goo +5 more
doaj +1 more source
cAMP-Signalling Regulates Gametocyte-Infected Erythrocyte Deformability Required for Malaria Parasite Transmission. [PDF]
, 2015 Blocking Plasmodium falciparum transmission to mosquitoes has been designated a strategic objective in the global agenda of malaria elimination. Transmission is ensured by gametocyte-infected erythrocytes (GIE) that sequester in the bone marrow and at ...
A Dawn +74 more
core +9 more sources
Response to pulmonary arterial hypertension drug therapies in patients with pulmonary arterial hypertension and cardiovascular risk factors. [PDF]
, 2014 The age at diagnosis of pulmonary arterial hypertension (PAH) and the prevalence of cardiovascular (CV) risk factors are increasing. We sought to determine whether the response to drug therapy was influenced by CV risk factors in PAH patients. We studied
Charalampopoulos, A +9 more
core +1 more source
Regiodivergent C3 and C4 Amination of Quinolines via Radical and Ionic Pathways
Angewandte Chemie, EarlyView.A regiodivergent strategy converts a single N‐aminoquinolinium precursor into either C3‐ or C4‐aminated quinolines. Nucleophile‐induced dearomatization diverges into light‐driven N‐centered radical capture (C3) or base‐promoted SNAr (C4), enabling rapid assembly of aminoquinoline libraries and late‐stage diversification.
Ye‐Eun Kim +3 more
wiley +2 more sources
EBioMedicine, 2019 Background: The phosphodiesterase-5 inhibitor (PDE5) sildenafil has emerged as a promising treatment for preeclampsia (PE). However, a sildenafil trial was recently halted due to lack of effect and increased neonatal morbidity.
Emilie Hitzerd +11 more
doaj +1 more source
Development of a human model for the study of effects of hypoxia, exercise, and sildenafil on cardiac and vascular function in chronic heart failure [PDF]
, 2015 Background: Pulmonary hypertension is associated with poor outcome in patients with chronic heart failure (CHF) and may be a therapeutic target. Our aims were to develop a noninvasive model for studying pulmonary vasoreactivity in CHF and characterize ...
Ciobanu, Andrea +12 more
core +2 more sources
Sildenafil does not reliably improve exercise performance in hypoxia: a systematic review
BMJ Open Sport & Exercise Medicine, 2019 Objective Sildenafil is a pulmonary vasodilator that may reduce the decrement in endurance performance in moderate hypoxia. We assessed the efficacy of sildenafil to improve performance in hypoxia.Data sources/eligibility Criteria We systematically ...
Eric Alexander Carter +3 more
doaj +1 more source
Selective inhibition of phosphodiesterases 4, 5 and 9 induces HSP20 phosphorylation and attenuates amyloid beta 1-42 mediated cytotoxicity [PDF]
, 2016 Phosphodiesterase (PDE) inhibitors are currently under evaluation as agents that may facilitate the improvement of cognitive impairment associated with Alzheimer's disease. Our aim was to determine whether inhibitors of PDEs 4,5 and 9 could alleviate the
Baillie, George S. +4 more
core +1 more source
Infectious Disease Reports, 2015 Sildenafil and bosentan are increasingly used for the treatment of pulmonary arterial hypertension (PAH) in HIV-infected patients. However, concerns exist about pharmacokinetic interactions among sildenafil, bosentan and antiretroviral drugs, including ...
Pierangelo Chinello +7 more
doaj +1 more source
Cardiac hypertrophy is inhibited by a local pool of cAMP regulated by phosphodiesterase 2 [PDF]
, 2015 Rationale: Chronic elevation of 3'-5'-cyclic adenosine monophosphate (cAMP) levels has been associated with cardiac remodelling and cardiac hypertrophy.
Aronsen, Jan M. +24 more
core +1 more source